Clinical TrialMay 1, 2026, 07:02 AM
MOLN MP0317 Phase 1 Data Positive; Phase 2 Trial Initiated
AI Summary
Molecular Partners AG announced the publication of positive Phase 1 clinical data for its tumor-localized CD40 agonist, MP0317, in Nature Cancer. The data confirmed MP0317's ability to modulate the tumor microenvironment with a favorable safety profile in patients with advanced solid tumors. Additionally, a randomized Phase 2 investigator-initiated trial of MP0317 in combination with standard-of-care for front-line cholangiocarcinoma is now open and enrolling patients, aiming to recruit 75 patients.
Key Highlights
- Positive Phase 1 data for MP0317 published in Nature Cancer, confirming tumor-localized CD40 activation.
- MP0317 demonstrated a favorable safety profile up to the highest tested dose in advanced cancer patients.
- One patient achieved an unconfirmed partial response and 14 patients stable disease out of 46 in Phase 1.
- Pharmacokinetic profile of MP0317 is well suited for combination treatment settings.
- Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma is open with patient dosing ongoing.
- The Phase 2 study aims to recruit 75 patients in France, randomized 2-to-1 (50 experimental, 25 control).
- Phase 2 combines MP0317 with standard-of-care chemotherapy and anti-PDL1 therapy.
Price Impact
More from MOLN